PKP2 Gene Therapy Vector for Arrhythmogenic Cardiomyopathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiac diseases, such as heart failure, are associated with high mortality and morbidity, and many therapeutic approaches are not suitable for patients with advanced heart failure and co-morbid diseases. There is a need for innovative methods that can effectively address the root cause of cardiac diseases.
Innovation Solution
The method involves delivering a therapeutic dose of a gene therapy vector to cardiomyocytes, which includes a nucleic acid sequence encoding for plakophilin-2 (PKP2) protein, using a viral vector such as adeno-associated virus (AAV). This approach aims to correct haploinsufficiency in PKP2-mutated cardiomyocytes, thereby treating or preventing cardiomyopathy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pharmacologic treatments are used for cardiac diseases, then treatment coverage is broad, but mortality and morbidity remain high
Solution Approach 1:
The patent uses adeno-associated virus (AAV) as a vector intermediary to deliver the PKP2 gene directly to cardiomyocytes. This viral mediator bypasses the limitations of pharmacologic treatments by enabling direct genetic correction at the cellular level, thereby improving treatment efficacy while reducing harmful outcomes associated with conventional drugs
2Ease of operation
If conventional therapeutic approaches are used, then treatment is simple, but they are not suitable for patients with advanced heart failure and co-morbid diseases
Solution Approach 1:
The patent employs cardiac-specific promoters (such as CMV or CAG promoters) to drive PKP2 expression specifically in cardiomyocytes. This localized approach ensures that the gene therapy targets the affected cells precisely, making the treatment adaptable to patients with advanced heart failure while maintaining targeted efficacy without affecting other organ systems
3Manufacturing precision
If gene therapy vectors are delivered to cardiomyocytes, then specific genetic correction is achieved, but delivery efficiency and targeting precision must be optimized
Solution Approach 1:
The patent utilizes adeno-associated virus (AAV) as a biological intermediary to achieve precise delivery of the PKP2 gene to cardiomyocytes. The AAV vector system naturally targets cardiac tissue and enables efficient transduction, thereby achieving high delivery precision without requiring complex external delivery devices or procedures
Data Source
AI summary
Disclosed are a composition and method of treating or preventing cardiomyopathy in a human subject. In some embodiments, the method comprises delivering a therapeutic dose of a gene therapy vector to cardiomyocytes of the human subject, wherein the gene therapy vector comprises a nucleic acid sequence encoding for PKP2.